Clinical Report: Initial DIAMOND Results Support OCS-01 Efficacy
Overview
The DIAMOND-1 trial results indicate that OCS-01 eye drops significantly improve best-corrected visual acuity (BCVA) and reduce retinal thickness in patients with diabetic macular edema (DME) at 12 weeks. These findings suggest OCS-01 as a promising noninvasive treatment option for DME.
Background
Diabetic macular edema (DME) is a leading cause of vision impairment in diabetic patients, necessitating effective treatment strategies. Current first-line therapies include intravitreal anti-VEGF injections, but many patients experience persistent edema despite treatment. The development of topical therapies like OCS-01 could provide a valuable alternative, potentially improving patient adherence and outcomes.
Data Highlights
| Outcome | OCS-01 | Vehicle Control | P-value |
|---|---|---|---|
| Mean BCVA Gain at Week 6 (ETDRS letters) | 7.2 | 3.1 | 0.007 |
| Proportion with ≥15-letter Improvement at Week 12 | 27.4% | 7.5% | 0.009 |
| Mean Central Retinal Thickness Reduction (μm) | 71 (treatment-naïve) | - | - |
| Mean Central Retinal Thickness Reduction (μm) | 52.3 (previously treated) | - | - |
Key Findings
- OCS-01 demonstrated a mean BCVA gain of 7.2 ETDRS letters at week 6 compared to 3.1 letters for vehicle (P=0.007).
- At week 12, 27.4% of patients treated with OCS-01 achieved a ≥15-letter improvement in BCVA versus 7.5% in the vehicle group (P=0.009).
- Mean central retinal thickness decreased by 71 μm in treatment-naïve eyes and 52.3 μm in previously treated eyes.
- OCS-01 was well tolerated, with increased intraocular pressure and macular edema as the most common adverse events.
- No treatment-related serious adverse events or cataract formation were reported during the trial.
Clinical Implications
The findings from the DIAMOND-1 trial support the use of OCS-01 as a viable noninvasive treatment option for patients with DME, particularly for those who may not respond adequately to current therapies. Clinicians should consider OCS-01 for patients seeking alternatives to intravitreal injections.
Conclusion
The initial results of the DIAMOND-1 trial indicate that OCS-01 is an effective treatment for DME, with significant improvements in visual acuity and retinal thickness. Further studies are warranted to confirm these findings and assess long-term outcomes.
References
- Retinal Physician, 2025 -- Initial DIAMOND Results Support OCS-01 Efficacy
- Ophthalmology Management, 2025 -- Positive Data Reported for Patients with DME
- Ophthalmology Management, 2025 -- Oculis Completes Enrollment for DIAMOND Phase 3 Trials for DME Therapy
- Retinal Physician, 2025 -- Oculis Completes Enrollment in DME Trials
- PubMed, 2026 -- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes
- Management of diabetic macular edema: from anti-VEGF to emerging therapies
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 - PubMed
- Positive Data Reported for Patients with DME | Ophthalmology Management
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.